Multiplex IHC and Multiplex IF (mIHC and mIF) Service
Biological processes do not occur in isolation. In the complex landscape of tissue pathology—whether in the Tumor Microenvironment (TME), neurodegenerative plaques, or autoimmune lesions—the interplay between immune cells and stromal components is just as critical as their individual presence.
Multiplex Immunohistochemistry (mIHC) and Multiplex Immunofluorescence (mIF) move beyond the limitations of standard single-marker staining. By visualizing multiple targets simultaneously on a single tissue section, these technologies allow researchers to map spatial relationships, define complex cellular phenotypes, and preserve the critical morphological context of the tissue.
Submit Your Request Now
×
- How to choose
- Workflow
- Panels
- Customized service
Choosing the Right Modality: mIHC vs. mIF
While both Multiplex Immunohistochemistry (mIHC) and Multiplex Immunofluorescence (mIF) aim to reveal the spatial biology of tissue, they utilize distinct detection systems suited for different investigative needs. Understanding the technical nuances and application scenarios of each is critical for study design.
| Feature | Multiplex IHC (Chromogenic) | Multiplex IF (Fluorescent) |
|---|---|---|
| Detection Principle | Enzyme-mediated deposition of colored precipitates (e.g., DAB, Teal, Red). | Fluorophore excitation and emission (often via Tyramide Signal Amplification). |
| Imaging Hardware | Standard Brightfield Microscope / Scanner. | Fluorescence Microscope / Multispectral Scanner. |
| Plex Capability | Typically limited to 3–4 markers simultaneously to avoid color blending ambiguities. | High multiplexing potential (6+ markers) with narrow-band emission filters. |
| Co-localization | Difficult to quantify; colors mix physically on the slide (e.g., Brown + Red). | Excellent; signals are distinct channels that can be digitally overlaid and quantified. |
| Tissue Context | Superior visualization of tissue architecture and morphology without digital reconstruction. | Good, but relies on nuclear stains (DAPI) or autofluorescence for morphological context. |
| Data Permanence | Permanent; slides do not fade and can be archived for years. | Signal can fade (photobleaching) over time; digital archiving is essential. |
Workflow of mIHC and mIF
High-order multiplexing requires a shift from traditional "cocktail" staining to a sequential, iterative approach. Whether utilizing the morphological clarity of mIHC or the high-plex capabilities of mIF, our workflow allows for the use of multiple primary antibodies from the same host species without cross-reactivity.
Our optimized protocol follows a cyclic "Stain-Image/Strip-Repeat" logic (for digital mIHC) or a "Stain-Strip-Stain" logic (for mIF), ensuring epitope stability and signal independence.
Phase 1: Foundation (Common to mIHC & mIF)
- Deparaffinization & Rehydration: Standard tissue preparation.
- Antigen Retrieval (HIER): A single, robust heating step unmasks epitopes. Our buffers are formulated to protect tissue morphology even through subsequent heating cycles.
- Blocking: Application of a universal blocking buffer to neutralize endogenous enzymes and prevent non-specific binding.
Phase 2: The Staining Cycle (Repeated for each Target)
- Primary Antibody Incubation: Binding of the specific primary antibody to the target antigen.
- HRP-Secondary Introduction: A polymer-HRP secondary antibody binds to the primary.
- The Divergence Point (Detection):
- For mIF: A Tyramide-Fluorophore is added. The HRP catalyzes the covalent deposition of the fluorophore directly onto the tissue.
- For mIHC: A Tyramide-Chromogen or high-sensitivity substrate (e.g., DAB, Teal, Red) is added to create a stable, colored precipitate.
- Antibody Stripping / Heat Deactivation: The slide is heated. This strips away the primary and secondary antibody complex, but the covalently bound fluorophore remains.
Phase 3: Counterstaining & Imaging
Counterstaining:
- mIF: DAPI is used to visualize nuclei and assist in cell segmentation.
- mIHC: Hematoxylin provides the nuclear contrast and anatomical context.
Imaging:
- mIF: Multispectral scanning or fluorescence microscopy captures distinct spectral channels.
- mIHC: Standard brightfield scanning captures the composite colored image.

Featured Application Panels
Our multiplex panels are curated to provide deep insights into specific biological mechanisms. By combining structural markers with functional and lineage-specific markers, these panels provide a holistic view of the cellular landscape.
Multiplex IF (Human Validated Panels) (mIFH Panels for human FFPE tissue specimens)
| Panel Name | Target Markers | Primary Application |
|---|---|---|
| Checkpoint Panel 1 | PD-L1, CD8, CD56, IFNγ, SOX10/PanCK, DAPI | Tumor immunity & NK cell profiling |
| Checkpoint Panel 2 | GAL9, LAG3, CD8, TIM3, CD155, MHCII | Exhaustion & inhibitory receptor mapping |
| T-Cell Activation | CD3, CD4, CD8, CD45RO, Grzm B, ICOS1, Ki67, DAPI | Activation state & memory profiling |
| T-Helper Lineage | CD3/CD4, CD8, FoxP3, T-bet, GATA3, RORγ, DAPI | Th1/Th2/Th17/Treg differentiation |
| Plasma Cell | CD3/CD4, CD8, CD20, IgG, CD138, Ki67, DAPI | B-cell maturation & antibody secretion |
| Myeloid Panel | CD11b, CD1a, GAL9, CD68, CD83, CD40, DAPI | Macrophage/DC polarization & activation |
| TLS Panel 1 | CD3/CD4, CD8, CD20, PNAd, DC-Lamp, Ki67 | Tertiary Lymphoid Structure (TLS) architecture |
| TLS Panel 2 | MADCAM, CD8, CD20, PNAd, RORγ, OLIG2, DAPI | TLS formation & neogenesis |
| IL-10 Panel | CD3/CD4, CD8, CD20, CD34, T-bet, IL-10, DAPI | Anti-inflammatory cytokine mapping |
| Immune Suppression | CD34, IDO1, ARG1, CD39, CD73, DAPI | Metabolic suppression & MDSC profiling |
| Ab Production | CD3/CD4, CD8, CD20, IFNγ, IgG, Ki67, DAPI | Functional B-cell analysis |
Multiplex IF (Mouse (Murine) Validated Panels) (mIFH Panels for murine FFPE tissue specimens)
| Panel Name | Target Markers | Primary Application |
|---|---|---|
| Murine TLS | CD4, CD8, CD19, CD11c, PNAd, CD34, DAPI | Characterizing lymphoid structures in mouse models |
| Murine T-Cell Activity | CD4, CD8, CD19, Grzm B, CD34, Ki67, DAPI | Cytotoxic activity & proliferation in mice |
Multiplex IHC Panels
| Panel Name | Target Markers | Primary Application |
|---|---|---|
| T-Cell Activation | CD3, Granzyme B, Ki67, PanCK | Cytotoxic T-cells in tumor nests |
| PD-L1 Checkpoint | CD8, CD68, PD-L1, PanCK | PD-L1 status on tumor vs. macrophages |
| Memory T-Cell | CD3, CD45RO, PD-1, PanCK | Exhausted memory cells in TME |
| APC Panel | CD11b, CD68, CD20, MHC II | Antigen presentation landscape |
Custom Panel Design Services
Every research hypothesis is unique. While our pre-validated panels cover core applications, novel discoveries often require unique marker combinations.
Developing a multiplex panel is complex; it requires balancing antibody species, fluorophore spectral overlap, and the order of antigen retrieval. Our Custom Panel Design service handles this complexity for you.
Our Service Includes:
- Consultation: Feasibility assessment of your target markers.
- Validation: Rigorous testing of antibody specificity and sensitivity.
- Optimization: Balancing signal-to-noise ratios for every channel.
- Protocol Transfer: We provide a fully optimized protocol ready for your lab.


